Company: LNAI
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001731122-25-001544
Chunk: 86

Company: Lunai Bioworks Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 86
---
 None of the goodwill is expected
to be deductible for income tax purposes.

The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.

Consolidated unaudited pro forma information: 

The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
three-month period ended September 30, 2024. These amounts have been estimated after applying the Company’s accounting policies:

Schedule of statement of operations

Revenues
 
$
318,918

Net loss
 
$
(44,499,586
)

The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.

    23

NOTE 11 — SUBSEQUENT EVENTS 

On November 4, 2025, the Company
issued 20,000 shares of Common Stock for consulting services valued at $16,680.

On October 30, 2025, the Company
cancelled 25,000 shares of Common Stock upon termination, previously issued to the former Chief Executive Officer of Renovaro Cube
valued at $177,500.

On October 29, 2025, the Company
issued 237,500 shares of Common Stock pursuant to a settlement agreement valued at $228,000.

On October 17, 2025, the Company
issued 20,000 shares of Common Stock for consulting services valued at $24,000.

24

Item 2. Management’s Discussion and Analysis of Financial Condition
and Results of Operations.

Forward-Looking Statement Notice 

Certain statements made in this
Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform
Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance, or achievements of Lunai Bioworks Inc. (“Lunai,”
and together with its subsidiaries, the “Company”, “we” or “us”) to be materially different from any
future results, performance or achievements expressed